Insider Selling: Eidos Therapeutics Inc (EIDX) Insider Sells 5,000 Shares of Stock

Eidos Therapeutics Inc (NASDAQ:EIDX) insider Jonathan C. Fox sold 5,000 shares of the stock in a transaction on Monday, April 15th. The shares were sold at an average price of $23.11, for a total value of $115,550.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

NASDAQ:EIDX traded down $0.81 during trading hours on Thursday, reaching $24.56. The company had a trading volume of 104,878 shares, compared to its average volume of 126,021. Eidos Therapeutics Inc has a 52 week low of $8.89 and a 52 week high of $29.74. The company has a market cap of $954.01 million and a PE ratio of -13.20.

Eidos Therapeutics (NASDAQ:EIDX) last issued its quarterly earnings data on Monday, April 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.01). As a group, equities analysts predict that Eidos Therapeutics Inc will post -1.52 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the business. New York State Common Retirement Fund acquired a new stake in shares of Eidos Therapeutics in the fourth quarter worth $69,000. BNP Paribas Arbitrage SA acquired a new position in Eidos Therapeutics during the 1st quarter worth approximately $80,000. JPMorgan Chase & Co. grew its holdings in Eidos Therapeutics by 112.9% during the 1st quarter. JPMorgan Chase & Co. now owns 3,947 shares of the company’s stock worth $93,000 after acquiring an additional 2,093 shares in the last quarter. Oppenheimer Asset Management Inc. acquired a new position in Eidos Therapeutics during the 4th quarter worth approximately $104,000. Finally, Bank of New York Mellon Corp acquired a new position in Eidos Therapeutics during the 3rd quarter worth approximately $137,000. Institutional investors and hedge funds own 30.09% of the company’s stock.

A number of research analysts recently commented on the company. BMO Capital Markets increased their target price on Eidos Therapeutics from $28.00 to $40.00 and gave the company an “outperform” rating in a research note on Wednesday. BTIG Research assumed coverage on shares of Eidos Therapeutics in a research report on Wednesday, April 17th. They set a “buy” rating and a $38.00 price target for the company. Zacks Investment Research raised shares of Eidos Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, April 15th. Finally, JPMorgan Chase & Co. raised shares of Eidos Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Wednesday, February 27th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $30.29.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Eidos Therapeutics Inc (EIDX) Insider Sells 5,000 Shares of Stock” was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/05/09/eidos-therapeutics-inc-eidx-insider-jonathan-c-fox-sells-5000-shares.html.

About Eidos Therapeutics

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

See Also: What is net income?

Insider Buying and Selling by Quarter for Eidos Therapeutics (NASDAQ:EIDX)

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.